Cyclooxygenase-I haplotype C50T/A-842G does not affect platelet response to aspirin

Thrombosis and Haemostasis

Volumn 101, Issue 4, 2009, Pages 687-690

  Pettinella, Caterina ^a   Romano, Mario ^a   Stuppia, Liborio ^a   Santilli, Francesca ^a   Liani, Rossella ^a   Davì, Giovanni ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Aspirin resistance; Pharmacogenetics; Polymorphisms

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CARDIOASPIRIN; CYCLOOXYGENASE 1; PROSTAGLANDIN SYNTHASE; THROMBOXANE B2; UNCLASSIFIED DRUG; 11 DEHYDRO THROMBOXANE B2; 11-DEHYDRO-THROMBOXANE B2; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS1 PROTEIN, HUMAN;

ADULT; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE; URINALYSIS; URINARY EXCRETION; BLOOD; CLINICAL TRIAL; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; GENE FREQUENCY; GENETICS; HETEROZYGOTE; HOMOZYGOTE; ITALY; METABOLISM; ORAL DRUG ADMINISTRATION; PHENOTYPE; THROMBOCYTE AGGREGATION; URINE;

ADMINISTRATION, ORAL; ADULT; ARACHIDONIC ACID; ASPIRIN; BLOOD PLATELETS; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; DRUG RESISTANCE; FEMALE; GENE FREQUENCY; HAPLOTYPES; HETEROZYGOTE; HOMOZYGOTE; HUMANS; ITALY; MALE; PHENOTYPE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; THROMBOXANE B2; YOUNG ADULT;

EID: 64849112905     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-11-0753     Document Type: Article

References (17)

1. Davì G, Patrono C. Platelet activation and atherothrombosis. New Engl J Med 2007; 357: 2482-2494.
2. Patrono C, Rodriguez LAG, Landolfi R, et al. Lowdose aspirin for the prevention of atherothrombosis. New Engl J Med 2005; 353: 2373-2383.
3. Halushka MK, Walker L P, Halushka P V. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clinical pharmacology and therapeutics 2003; 73: 122-130.
4. Maree AO, Curtin RJ, Chubb A, et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005; 3: 2340-2345.
5. Gonzalez-Conejero R, Rivera J, Corral J, et al. Biological assessment of aspirin efficacy on healty individuals, heterogeneous response or aspirin failure? Stroke 2005; 36: 276-280.
6. Lepantalo A, Mikkelsson J, Reséndiz JC, et al. Polymorphisms of COX-1 and GP VI associate with antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 2006; 95: 253-259.
7. Patrono C, Ciabattoni G, Pinca E, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980; 17: 317-327.
8. 2 in man. Biochim Biophys Acta 1989; 992: 66-70.
9. Santilli F, Rocca B, De Cristofaro R, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays. Implications for aspirin 'resistance'. JACC 2009; 53: 667-677.
10. Clappers N, van Oijen MGH, Sundaresan S, et al. The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost 2008; 100: 70-75.
11. Arisawa T, Tahara T, Shibata T, et al. Association between genetic polymorphisms in the cyclooxygenase-1 gene promoter and peptic ulcers in Japan. Int J Mol Med 2007; 20: 373-378.
12. Qing L, Bi-Lian C, V u r a l O , et al. Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin. Pharmacogenomics 2007; 8: 577-586.
13. Eikelboom J W, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular events. Circulation 2002; 105: 1650-1655.
14. Zimmermann N, Hohlfeld T. Clinical implications of aspirin resistance. Thromb Haemost 2008; 100: 379-390.
15. Guthikonda S, Mangalpally K, Vaduganathan M, et al. Increased platelet sensitivity among individuals with aspirin resistance - Platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy. Thromb Haemost 2008; 100: 83-89.
16. Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 2008; 66: 222-232.
17. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003; 1: 1710-1713.